Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Exelixix
Exelixix
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Flag link:
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Flag link:
Exelixis Licenses PI3K-Delta Program to Merck
Exelixis Licenses PI3K-Delta Program to Merck
Yahoo
Merck
Exelixix
P13K-Delta
XL-499
Flag link:
